Head Of The Class: A Star Stands Out Among 2014 Drug Launches

Gilead’s Sovaldi earned a spot in the record books – and the hearts of drug marketers – generating $8.55 billion in the first nine months of 2014. Despite controversy over Sovaldi’s high price, Gilead defended the drug’s value and executed flawlessly on the launch. Other 2014 drug launches were slow out of the gates, as the bar for new drugs continues to grow.